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re-use of eDiaries previously used by patients doing fingerstick tests poses a low and 
acceptable risk; flexibility for handling measurements should be incorporated in the 
eDiary design including batch and individual reporting, reporting hypoglycaemic 
events as part of a meal event or as a standalone event and edit checks should be 
included to identify where a number of low measurements relate to the same event; 
there should be clear guidance to patientson how to transfer measurements to the 
eDiary; a method for managing control test measurementsshould be incorporated; 
and integrating glucometer measurements decreases patient burden and increases 
patient engagement.
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Objectives: The 347 million people who live with diabetes face an array of daily 
disease management tasks, e. g. measuring blood glucose, keeping track of the nutri-
tional value of meals, and monitoring insulin usage. Diabetes trials vary in method-
ology, level of patient burden, volume of data captured and patient compliance. Our 
aim was to develop an electronic data capture system for use in clinical trials which 
would decrease patient burden while increasing compliance and improving data 
quality. MethOds: We developed a diabetes specific, electronic, event driven diary 
for capturing data relevant for clinical trials. Iterations of the diary were tested in 
diabetes patients via focus groups and one-on-one usability evaluations. Feedback 
was analysed to understand the typical day-to-day experience of living with diabe-
tes, and to examine the impact and acceptability of a tailored electronic solution. 
Feedback was incorporated into a refined solution for use in clinical trials. Results: 
The nature of diabetes means that patients are typically very actively engaged in 
managing their disease, although a lot of variation was seen in patients and their 
management routines. The requirement for multiple devices and high volume of 
data was also reported as burdensome. The focus groups and usability studies high-
lighted the benefit of providing a flexible solution, as well as redesigning the diary 
from unstructured blood glucose measurement reporting to event driven reporting. 
This redesign met the needs of patients, as well as the requirements of clinical trial 
protocols. Patients agreed that they would prefer this integrated, intuitive solution 
over traditional paper and electronic solutions. cOnclusiOns: When faced with 
the task of recording patient data in diabetes, a well-designed and thoroughly tested 
electronic solution can reduce burden and increase patient satisfaction. This in turn 
improves compliance, data quality and overall study efficiency, while meeting the 
needs of all stakeholders.
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Objectives: Treatments for Type 2 Diabetes Mellitus (T2DM) are associated with 
varying effectiveness and safety profiles. Patients’ preferences for each of the medi-
cation characteristics that yield these varying profiles can be assessed through 
discrete choice experiments (DCEs). This study expands on the knowledge from 
two previous T2DM DCE studies conducted in the United Kingdom (UK) and the 
United States (US), and was aimed at evaluating the relative importance of medi-
cation attributes that influence medication choice among participants with T2DM 
from Germany. MethOds: A web-based DCE was conducted among patients with 
self-reported T2DM from Germany. The DCE was designed to examine 7 attributes 
of T2DM medications (efficacy, urinary tract infection/genital infection side effects, 
nausea/other gastrointestinal side effects, weight change, and hypoglycemic events, 
treatment in case of low blood sugar, and blood pressure). Part-worth utilities were 
estimated using multi-logit models, and relative importance [RI] values were cal-
culated for each attribute. Results: N= 600 Participants with T2DM completed the 
study (50% male; mean age= 58.2 years SD= 10.0; BMI= 32.4, SD= 6.8). The RI values 
for the attributes in order of importance were: treatment in case of low blood sugar 
(22.5%), hypoglycemic events (18.1%), weight change (17.5%), efficacy (15.0%), nau-
sea/other gastrointestinal side effects (12.9%), UTI/genital infection side effects 
(7.9%), and blood pressure (6.0%). cOnclusiOns: The results of this study suggest 
that hypoglycemic events and the interventions required in the case of such events 
are of great importance to patients; these two attributes represent over 40% of the 
variance in patients’ medication decisions. Change in body weight as a consequence 
of treatment was also an important attribute to patients. The results may help treat-
ment providers and payers to understand the preferences of patients with T2DM. 
Understanding these preferences may be useful in devising strategies for success-
fully engaging and maintaining patients on T2DM treatments.
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Objectives: Hypoglycaemia is the main side-effect of insulin therapy and can 
prevent optimal diabetes management. Real-world data on the frequency and 
impact of non-severe (self-treated) hypoglycaemic events are scarce. Self-reported 
frequency of non-severe hypoglycaemic events (NSHEs), their impact on personal 
well-being, work productivity and health care resource use, and patient–physician 
communication following non-severe events, were examined in people taking insu-
lin. MethOds: Adults in the UK aged > 15 years with Type 1 or insulin-treated Type 2 
diabetes mellitus (T1DM or T2DM) completed ≤ 4 questionnaires at weekly intervals 
(7-day recall). Severe hypoglycaemic events (requiring external assistance) are not 
more health care provider visits in the past six months (11.7 vs. 8.9) compared with 
matched controls (n= 286) (all p< .05). cOnclusiOns: DME was more commonly 
reported by patients with diabetes and its presence was associated with a significant 
humanistic and economic burden in the 5EU.
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Objectives: Hyponatraemia (HN) is estimated to occur in 15% of all hospitalised 
patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) 
being one of the most common aetiologies. Patients treated with tolvaptan have 
demonstrated improvements in health related quality of life (HRQL) in the SALT I 
& II randomised controlled trials. The objective of this study was to map the SF-12 
responses from SALT I & II to EQ-5D using a publically available algorithm and 
predict the change in EQ-5D associated with tolvaptan. MethOds: SF-12 scores 
from the pooled SALT I & II studies were converted to EQ-5D scores using a map-
ping algorithm developed by Gray, et. al 2006. Simulated EQ-5D scores were then 
used to estimate changes in EQ-5D from baseline at day 30 using ordinary least 
squares regression (OLS) as a function of baseline characteristics, treatment arm and 
achievement of sodium correction (NA+) at day 4 (> 135 mmol/l). A preferred model 
was selected based on the highest adjusted R-squared. Secondary analyses looked 
at change from baseline in EQ-5D at day 7, day 14 and at 7 day follow-up following 
treatment discontinuation. Results: The preferred model included baseline age, 
gender, sodium level, EQ-5D and a tolvaptan indicator variable. Based on this model, 
tolvaptan was associated with a positive increase in simulated EQ-5D of 0.10 (n= 164, 
p= 0.03) at day 30 vs. placebo. After 7 days follow-up, tolvaptan was associated with a 
positive, but non- statistically significant effect of 0.04 (n= 74, p= 0.54). No effect was 
observed at day 7 (n= 76, p= 0.90) or at day 14 (n= 85, p= 0.84). Sodium correction did 
not appear to be a statistically significant predictor of HRQL. cOnclusiOns: The 
preferred model indicated a statistically significant improvement in HRQL associ-
ated with tolvaptan use at day 30. Further research is required to establish whether 
sodium correction has an effect of HRQL.
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Objectives: This 4-wk, Phase 3b, multicentre, open-label, single-arm, outpatient 
study evaluated the safe and effective use of the Single-Use Pen (SUP) in patients 
with type 2 diabetes (T2D) who were naïve to self-injection or injecting others. The 
SUP contains a pre-filled syringe and automates needle insertion, retraction, and 
drug delivery; specifically designed for once-weekly glucagon-like peptide-1 recep-
tor agonist, dulaglutide. Patient-reported outcomes (PROs) related to self-injection 
and to the SUP were important secondary outcomes. MethOds: Patients (N= 211) 
were trained on correct injection technique with the SUP containing 0.5 mL placebo 
prior to initial self-injection. PRO measures were completed by patients after final 
injection or at early termination to evaluate device ease of use, experience (including 
satisfaction/confidence), and key device features. Site trainers rated how easy/dif-
ficult it was to train the patient to use the SUP. Results: 99.0% of patients found the 
device easy to use. Patients found it easy to hold the SUP when injecting and to push 
the button to inject (97.6% and 98.1%, respectively). 97.1% of patients were satisfied 
with the overall injection experience, 96.7% of patients were confident they could 
identify when the full dose was delivered, and 99.0% were confident in their overall 
ability to use the SUP. Patients liked not having to attach (99.0%), touch (98.6%), or see 
(95.7%) the needle. 95.7% of patients also liked hearing the click indicating the dose 
was complete and 94.8% liked the automatic needle insertion. Finally, 92.4% of site 
trainers found it easy to train patients on how to use the SUP. cOnclusiOns: This 
study demonstrated the SUP could be used safely and effectively by injection-naïve 
patients with T2D; PRO results indicated patient satisfaction with the SUP injection 
experience. A positive injection experience may be an important factor for some 
patients and providers when initiating injectable therapy.
PDB126
BeST PracTIceS In InTegraTIng home glucomeTer meaSuremenTS WITh 
elecTronIc PaTIenT rePorTeD ouTcomeS (ePro) In clInIcal TrIalS
Garner K.
CRF Health, London, UK
Objectives: Monitoring glycaemic control is important in diabetes clinical trials 
and is also relevant for some oncology trials. It is possible to seamlessly integrate 
blood glucose measurements with clinical trial data via Bluetooth. This integration 
reduces transcription errors and improves accuracy and completeness of data, while 
reducing burden on patients. Our aim was to explore best practices in integrating 
measurements with ePRO. MethOds: A review of best practice and experience in 
blood glucose measurement data integration was undertaken and the findings were 
incorporated into a solution for use in clinical trials. A systematic literature review 
was also undertaken to assess the contamination risk to individuals handling and 
re-using electronic diaries (eDiary) previously used by patients doing fingerstick 
tests for blood glucose measurement. We defined search terms and undertook a 
PubMed and internet search. All documents that were identified as possibly relevant 
were reviewed and summarised. Results: The review revealed key features and 
activities related to planning, design, testing and delivery that are important for 
successful integration of blood glucose measurements with ePRO data. The litera-
ture review confirmed that the risk in handling and re-using eDiaries previously 
used by patients doing fingerstick tests was very low. cOnclusiOns: Handling and 
